Q2-2022 Dermatology Update
Q2-2022 Dermatology Update
Dermatology deal activity continued its rebound towards 2018 and 2019 levels after a relatively slow 2020 and 2021, primarily driven by strategic add on transactions and secondary buyouts. The quarter saw a number of notable transactions that will have a meaningful impact on the dermatology space, particularly, as it relates to M&A. One such deal was Sheridan Capital’s exit of Dermatologists of Central States (DOCS) to private equity firm SkyKnight Capital, the third secondary transaction in as many quarters. Another landmark deal occurring this quarter was the merger between West Dermatology and Platinum Dermatology Partners, two sizable, regional platforms spanning multiple states and over 100 providers. Provident expects transaction volume and valuations to remain elevated, but is tracking macroeconomic factors that may ultimately impact dealmaking in the quarters to come.
To print and download the full Dermatology report, please click below…